Telescope Innovations (TELI) Q3 2025 earnings summary

Executive summary

• Achieved revenues of $1.4 million in Q3 FY2025, driven by strong sales of DirectInject-LC, with growth in both sales and order pipelines compared to Q3 FY2024.

• Advanced operational milestones with the launch of DirectInject-LC in Asia, and progress in Self-Driving Lab development with Pfizer.

• Shipped first battery-grade lithium sulfide samples to major industry groups, marking commercial advancement in lithium technology.

Financial highlights

• Revenues reached $1,394,542, up from $1,224,351 in Q3 FY2024.

• Expenses increased to $1,896,028 from $1,424,650 year-over-year.

• Adjusted EBITA loss was $99,466, compared to a $51,413 loss in the same quarter last year.

Outlook and guidance

• Financial results are in line with FY2025 budget and targets, with continued growth expected from core technologies and strategic partnerships.